{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:11Z","timestamp":1790483291532,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T00:00:00Z","timestamp":1452297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40273-015-0373-9","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T12:35:38Z","timestamp":1452342938000},"page":"551-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis\u00a0C Treatment with Direct-Acting Antivirals"],"prefix":"10.1007","volume":"34","author":[{"given":"Jagpreet","family":"Chhatwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"key":"373_CR1","unstructured":"World Health Organization. Hepatitis\u00a0C fact sheet. World Health Organization. 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en . Accessed 8 Jun\u00a02015."},{"issue":"25","key":"373_CR2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","volume":"364","author":"HR Rosen","year":"2011","unstructured":"Rosen HR. Chronic hepatitis\u00a0C infection. N Engl J Med. 2011;364(25):2429\u201338.","journal-title":"N Engl J Med"},{"issue":"5","key":"373_CR3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston MM, et al. Chronic hepatitis\u00a0C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293\u2013300.","journal-title":"Ann Intern Med"},{"issue":"7","key":"373_CR4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","volume":"52","author":"BL Pearlman","year":"2011","unstructured":"Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis\u00a0C virus infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889\u2013900.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"373_CR5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, et al. Boceprevir for untreated chronic HCV genotype\u00a01 infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"20","key":"373_CR6","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMe1303818","volume":"368","author":"JP Drenth","year":"2013","unstructured":"Drenth JP. HCV treatment\u2014no more room for interferonologists? N Engl J Med. 2013;368(20):1931\u20132.","journal-title":"N Engl J Med"},{"issue":"16","key":"373_CR7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype\u00a01 infection. N Engl J Med. 2014;370(16):1483\u201393.","journal-title":"N Engl J Med"},{"issue":"3","key":"373_CR8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M14-0095","volume":"161","author":"M Kabiri","year":"2014","unstructured":"Kabiri M, et al. The changing burden of hepatitis\u00a0C in the United States: model-based predictions. Ann Intern Med. 2014;161(3):170\u201380.","journal-title":"Ann Intern Med"},{"issue":"6","key":"373_CR9","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, et al. Chronic hepatitis\u00a0C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164\u201370.","journal-title":"Hepatology."},{"key":"373_CR10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMe1401508","volume":"370","author":"JH Hoofnagle","year":"2014","unstructured":"Hoofnagle JH, Sherker AH. Therapy for hepatitis\u00a0C\u2014the costs of success. N Engl J Med. 2014;370:1552\u20133.","journal-title":"N Engl J Med"},{"key":"373_CR11","unstructured":"Silverman E. \u2018Unsustainable for our country\u2019: Express Scripts calls out pricey meds. Wall Street Journal. 2014. http:\/\/blogs.wsj.com\/corporate-intelligence\/2014\/04\/08\/unsustainable-for-our-country-express-scripts-calls-out-pricey-meds . Accessed 11 Apr 2014."},{"key":"373_CR12","unstructured":"First DataBank, Inc. Drug pricing policy. First DataBank, Inc. 2014. http:\/\/www.firstdatabank.com\/Support\/drug-pricing-policy.aspx . Accessed 6 Mar 2014."},{"issue":"19","key":"373_CR13","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.29512","volume":"121","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, Mathisen M, Kantarjian HM. Are high drug prices of hematologic malignancies justified? A critical analysis. Cancer. 2015;121(19):3372\u20139.","journal-title":"Cancer."},{"issue":"4","key":"373_CR14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"373_CR15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1524-4733.2004.75012.x","volume":"7","author":"U Siebert","year":"2004","unstructured":"Siebert U, et al. Systematic assessment of decision models in Parkinson\u2019s disease. Value Health. 2004;7(5):610\u201326.","journal-title":"Value Health"},{"issue":"2","key":"373_CR16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40258-013-0071-8","volume":"12","author":"U Rochau","year":"2014","unstructured":"Rochau U, et al. Systematic assessment of decision-analytic models for chronic myeloid leukemia. Appl Health Econ Health Policy. 2014;12(2):103\u201315.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"373_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, et al. Modeling good research practices\u2014overview. Med Decis Making. 2012;32(5):667\u201377.","journal-title":"Med Decis Making"},{"issue":"5","key":"373_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361\u20137.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"373_CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","volume":"162","author":"BP Linas","year":"2015","unstructured":"Linas BP, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis\u00a0c virus genotype 2 or\u00a03 infection. Ann Intern Med. 2015;162(9):619\u201329.","journal-title":"Ann Intern Med."},{"issue":"1","key":"373_CR20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3111\/13696998.2013.844159","volume":"17","author":"S Cure","year":"2014","unstructured":"Cure S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis\u00a0C genotype\u00a01 patients. J Med Econ. 2014;17(1):77\u201387.","journal-title":"J Med Econ"},{"issue":"1","key":"373_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3111\/13696998.2013.860033","volume":"17","author":"S Cure","year":"2014","unstructured":"Cure S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis\u00a0C genotype\u00a01 patients. J Med Econ. 2014;17(1):65\u201376.","journal-title":"J Med Econ"},{"issue":"9","key":"373_CR22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3111\/13696998.2015.1040024","volume":"18","author":"S Cure","year":"2015","unstructured":"Cure S, et al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis\u00a0C in Italy. J Med Econ. 2015;18(9):678\u201390.","journal-title":"J Med Econ"},{"key":"373_CR23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12876-015-0320-4","volume":"15","author":"S Zhang","year":"2015","unstructured":"Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis\u00a0C in the US. BMC Gastroenterol. 2015;15:98.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"373_CR24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.dld.2014.06.009","volume":"46","author":"S Petta","year":"2014","unstructured":"Petta S, et al. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype\u00a01 chronic hepatitis\u00a0C. Dig Liver Dis. 2014;46(10):936\u201342.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"373_CR25","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.27010","volume":"59","author":"S Petta","year":"2014","unstructured":"Petta S, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype\u00a01 chronic hepatitis\u00a0C. Hepatology. 2014;59(5):1692\u2013705.","journal-title":"Hepatology"},{"issue":"2","key":"373_CR26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H Thein","year":"2008","unstructured":"Thein H, et al. Estimation of stage specific fibrosis progression rates in chronic hepatitis\u00a0C virus infection: a meta analysis and meta regression. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology"},{"issue":"6","key":"373_CR27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","volume":"162","author":"M Najafzadeh","year":"2015","unstructured":"Najafzadeh M, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis\u00a0C virus. Ann Intern Med. 2015;162(6):407\u201319.","journal-title":"Ann Intern Med"},{"issue":"3","key":"373_CR28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.25734","volume":"56","author":"C Camma","year":"2012","unstructured":"Camma C, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype\u00a01 chronic hepatitis\u00a0C. Hepatology. 2012;56(3):850\u201360.","journal-title":"Hepatology"},{"issue":"6","key":"373_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, et al. Cost-effectiveness and budget impact of hepatitis\u00a0C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397\u2013406.","journal-title":"Ann Intern Med"},{"issue":"3","key":"373_CR30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAD.0000000000000093","volume":"28","author":"BP Linas","year":"2014","unstructured":"Linas BP, et al. The cost-effectiveness of improved hepatitis\u00a0C virus therapies in HIV\/hepatitis\u00a0C virus coinfected patients. Aids. 2014;28(3):365\u201376.","journal-title":"Aids"},{"issue":"2","key":"373_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","volume":"61","author":"DB Rein","year":"2015","unstructured":"Rein DB, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis\u00a0C virus. Clin Infect Dis. 2015;61(2):157\u201368.","journal-title":"Clin Infect Dis."},{"key":"373_CR32","first-page":"118","volume-title":"The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis\u00a0C infection: a technology assessment","author":"JA Tice","year":"2014","unstructured":"Tice JA, Ollendorf DA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis\u00a0C infection: a technology assessment. Boston: Institute for Clinical and Economic Review; 2014. p. 118."},{"issue":"1","key":"373_CR33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.27151","volume":"60","author":"LM Hagan","year":"2014","unstructured":"Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype\u00a01 hepatitis\u00a0C virus in interferon-ineligible\/intolerant individuals. Hepatology. 2014;60(1):37\u201345.","journal-title":"Hepatology"},{"issue":"8","key":"373_CR34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jval.2014.07.011","volume":"17","author":"E Warren","year":"2014","unstructured":"Warren E, Wright A, Jones B. Cost-effectiveness of telaprevir in patients with genotype\u00a01 hepatitis\u00a0C in Australia. Value Health. 2014;17(8):792\u2013800.","journal-title":"Value Health"},{"issue":"6","key":"373_CR35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40258-014-0120-y","volume":"12","author":"A Vellopoulou","year":"2014","unstructured":"Vellopoulou A, et al. Cost utility of telaprevir\u2013PR (peginterferon\u2013ribavirin) versus boceprevir\u2013PR and versus PR alone in chronic hepatitis\u00a0C in the Netherlands. Appl Health Econ Health Policy. 2014;12(6):647\u201359.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"373_CR36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","volume":"15","author":"R Pitman","year":"2012","unstructured":"Pitman R, et al. Dynamic transmission modeling: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force\u20135. Value Health. 2012;15(6):828\u201334.","journal-title":"Value Health"},{"issue":"5","key":"373_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40273-015-0254-2","volume":"33","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, He T. Economic evaluations with agent-based modelling: an introduction. Pharmacoeconomics. 2015;33(5):423\u201333.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"373_CR38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/M14-0602","volume":"161","author":"S Liu","year":"2014","unstructured":"Liu S, et al. Sofosbuvir-based treatment regimens for chronic, genotype\u00a01 hepatitis\u00a0C virus infection in US incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546\u201353.","journal-title":"Ann Intern Med"},{"issue":"11","key":"373_CR39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jvh.12409","volume":"22","author":"S Cure","year":"2015","unstructured":"Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis\u00a0C-infected patients. J Viral Hepat. 2015;22(11):882\u20139.","journal-title":"J Viral Hepat."},{"issue":"5","key":"373_CR40","doi-asserted-by":"crossref","first-page":"e0126984","DOI":"10.1371\/journal.pone.0126984","volume":"10","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis\u00a0C. PLoS One. 2015;10(5):e0126984.","journal-title":"PLoS One"},{"issue":"5","key":"373_CR41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, et al. Model parameter estimation and uncertainty analysis. Med Decis Making. 2012;32(5):722\u201332.","journal-title":"Med Decis Making"},{"issue":"12","key":"373_CR42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jvh.12111","volume":"20","author":"LM Hagan","year":"2013","unstructured":"Hagan LM, et al. All-oral, interferon-free treatment for chronic hepatitis\u00a0C: cost-effectiveness analyses. J Viral Hepat. 2013;20(12):847\u201357.","journal-title":"J Viral Hepat"},{"issue":"7","key":"373_CR43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.clinthera.2015.05.003","volume":"37","author":"K Athanasakis","year":"2015","unstructured":"Athanasakis K, et al. Boceprevir for chronic genotype\u00a01 hepatitis\u00a0C virus in the current health care setting in Greece: a cost-effectiveness analysis. Clin Ther. 2015;37(7):1529\u201340.","journal-title":"Clin Ther"},{"issue":"5","key":"373_CR44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, et al. Model transparency and validation: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force\u20137. Med Decis Making. 2012;32(5):733\u201343.","journal-title":"Med Decis Making"},{"issue":"11","key":"373_CR45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2013.05.014","volume":"11","author":"K Chan","year":"2013","unstructured":"Chan K, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype\u00a01 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2013;11(11):1503\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"373_CR46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2013.05.019","volume":"59","author":"C Camma","year":"2013","unstructured":"Camma C, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype\u00a01 chronic hepatitis\u00a0C. J Hepatol. 2013;59(4):658\u201366.","journal-title":"J Hepatol"},{"issue":"8","key":"373_CR47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/gutjnl-2014-307772","volume":"64","author":"R San Miguel","year":"2015","unstructured":"San Miguel R, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis\u00a0C. Gut. 2015;64(8):1277\u201388.","journal-title":"Gut."},{"key":"373_CR48","doi-asserted-by":"crossref","unstructured":"Gimeno-Ballester V, Mar J, San Miguel R. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naive patients plus chronic hepatitis\u00a0C. Expert Rev Pharmacoecon Outcomes Res (Epub 2015 Sep\u00a01).","DOI":"10.1586\/14737167.2015.1081061"},{"issue":"10","key":"373_CR49","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3111\/13696998.2015.1044457","volume":"18","author":"K Westerhout","year":"2015","unstructured":"Westerhout K, et al. A cost utility analysis of simeprevir used with peginterferon\u00a0+\u00a0ribavirin in the management of genotype\u00a01 hepatitis\u00a0C virus infection, from the perspective of the UK National Health Service. J Med Econ. 2015;18(10):838\u201349.","journal-title":"J Med Econ."},{"issue":"6","key":"373_CR50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apt.13081","volume":"41","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, et al. Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis\u00a0C virus genotype\u00a01 infection. Aliment Pharmacol Ther. 2015;41(6):544\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"373_CR51","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","volume":"32","author":"U Siebert","year":"2012","unstructured":"Siebert U, et al. State-transition modeling: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force. Med Decis Making. 2012;32(5):690\u2013700.","journal-title":"Med Decis Making"},{"issue":"1","key":"373_CR52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0272989X15585121","volume":"36","author":"EH Elbasha","year":"2016","unstructured":"Elbasha EH, Chhatwal J. Theoretical foundations and practical applications of within-cycle correction methods. Med Decis Making. 2016;36(1):115\u201331.","journal-title":"Med Decis Making."},{"issue":"1","key":"373_CR53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0272989X15585121","volume":"36","author":"EH Elbasha","year":"2016","unstructured":"Elbasha EH, Chhatwal J. Theoretical foundations and practical applications of within-cycle correction methods. Med Decis Making. 2016;36(1):115\u201331.","journal-title":"Med Decis Making."},{"issue":"8","key":"373_CR54","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","volume":"14","author":"R Townsend","year":"2011","unstructured":"Townsend R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis\u00a0C. Value Health. 2011;14(8):1068\u201377.","journal-title":"Value Health"},{"issue":"19","key":"373_CR55","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2169\/internalmedicine.51.8404","volume":"51","author":"K Takahashi","year":"2012","unstructured":"Takahashi K, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis\u00a0C virus infection. Intern Med. 2012;51(19):2745\u20137.","journal-title":"Intern Med"},{"key":"373_CR56","unstructured":"Terrault N, et al. Treatment outcomes with 8, 12 and 24\u00a0week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis\u00a0C infection: analysis of a multicenter prospective, observational study. The Liver Meeting\u00ae 2015. American Association for the Study of Liver Diseases, San Fransisco; 13\u201317 Nov 2015."},{"issue":"4","key":"373_CR57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","volume":"156","author":"S Liu","year":"2012","unstructured":"Liu S, et al. New protease inhibitors for the treatment of chronic hepatitis\u00a0C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279\u201390.","journal-title":"Ann Intern Med"},{"issue":"10","key":"373_CR58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40273-013-0080-3","volume":"31","author":"A Blazquez-Perez","year":"2013","unstructured":"Blazquez-Perez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis\u00a0C patients. Pharmacoeconomics. 2013;31(10):919\u201331.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"373_CR59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","volume":"16","author":"J Chhatwal","year":"2013","unstructured":"Chhatwal J, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis\u00a0C genotype\u00a01 infection in the United States. Value Health. 2013;16(6):973\u201386.","journal-title":"Value Health"},{"issue":"1","key":"373_CR60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40258-012-0007-8","volume":"11","author":"EH Elbasha","year":"2013","unstructured":"Elbasha EH, et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis\u00a0C virus genotype\u00a01 infection in Portugal. Appl Health Econ Health Policy. 2013;11(1):65\u201378.","journal-title":"Appl Health Econ Health Policy"},{"key":"373_CR61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2334-13-190","volume":"13","author":"SA Ferrante","year":"2013","unstructured":"Ferrante SA, et al. Boceprevir for previously untreated patients with chronic hepatitis\u00a0C genotype\u00a01 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013;13:190.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"373_CR62","doi-asserted-by":"crossref","first-page":"e90295","DOI":"10.1371\/journal.pone.0090295","volume":"9","author":"AJ Brogan","year":"2014","unstructured":"Brogan AJ, et al. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis\u00a0C. PLoS One. 2014;9(3):e90295.","journal-title":"PLoS One"},{"issue":"2","key":"373_CR63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3851\/IMP2825","volume":"20","author":"YY Dan","year":"2015","unstructured":"Dan YY, et al. Cost-effectiveness of boceprevir co-administration versus pegylated interferon \u03b12b and ribavirin only for patients with hepatitis\u00a0C genotype\u00a01 in Singapore. Antivir Ther. 2015;20(2):209\u201316.","journal-title":"Antivir Ther."},{"issue":"6","key":"373_CR64","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.12871","volume":"40","author":"S Saab","year":"2014","unstructured":"Saab S, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis\u00a0C virus genotype\u00a01 infection. Aliment Pharmacol Ther. 2014;40(6):657\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"373_CR65","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/jvh.12311","volume":"22","author":"H Leleu","year":"2015","unstructured":"Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis\u00a0C. J Viral Hepat. 2015;22(4):376\u201383.","journal-title":"J Viral Hepat"},{"issue":"7","key":"373_CR66","first-page":"A390","volume":"15","author":"R Odhiambo","year":"2012","unstructured":"Odhiambo R, et al. Economic evaluation of boceprevir for the treatment of patients with genotype\u00a01 chronic hepatitis\u00a0C virus infection in Hungary. J Health Econ Outcomes Res. 2012;15(7):A390.","journal-title":"J Health Econ Outcomes Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0373-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0373-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T09:53:00Z","timestamp":1567504380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0373-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}